Johan Kördel
Senior Partner @ Lundbeckfonden Ventures
Copenhagen, Denmark
Johan Kördel is a senior partner with Lundbeckfond Ventures, a life science venture fund established by the Lundbeck Foundation in 2009. Johan was previously co-founder and CEO of Sound Biotech ApS and co-founder and Senior Vice President of Research and Business Development of Biovitrum AB. Prior to these positions Johan worked almost a decadein the pharmaceutical company Pharmacia with management, research, early development, portfolio management, business development and alliance management. Johan has co-founded other biotech companies and been appointed to numerous board positions both in private and public companies. Johan is an associate professor in Physical Chemistry at the University of Lund, Sweden.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Johan Kördel invests in
Stages Johan Kördel invests in
Countries Johan Kördel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (47%)
- Medical 7 (37%)
- Therapeutics 6 (32%)
- Biopharma 5 (26%)
- Health Care 4 (21%)
Stage
- Series A 5 (26%)
- Series B 3 (16%)
- Series C 3 (16%)
- Venture - Series Unknown 3 (16%)
- Seed 1 (5%)
Country
- United States 7 (37%)
- Sweden 2 (11%)
- France 1 (5%)
- Denmark 1 (5%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BOOST Pharma is a biotechnology research company developing a stem cell therapy for the treatment of osteogenesis imperfecta. It is based on novel mesenchymal stem cells that have high bone-forming capabilities that migrate to the bone of patients where they will engraft, and start bone formation.It was founded in 2019 and is headquartered inCopenhagen, Denmark. | $3.6M / Venture - Series Unknown / Nov 03, 2025 | ||
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $18.4M / Series A / Jan 09, 2025 | ||
| Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases. | $4.1M / Seed / Nov 10, 2022 | ||
| Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating andlife-threatening diseases that affect people with compromised immune systems.Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California. | $53M / Series C / May 19, 2020 | ||
| Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life ofpatients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting.The company was founded in 2014 and is headquartered in San Diego, California. | $50M / Series A / May 20, 2019 | ||
| Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $4.1M / Venture - Series Unknown / Jun 15, 2018 | ||
| Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating andlife-threatening diseases that affect people with compromised immune systems.Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California. | $67M / Series C / Aug 01, 2017 | ||
| Enterome is an integrated company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics.Enterome is focused on the identification of the bioactive molecules that are differentially expressed, secreted and regulated by the gut microbiome, whichplay a central role in the regulation of key aspects of human physiology and the immune system. | $33.7M / Series D / Jan 01, 2017 | ||
| BONESUPPORT is a medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures. The company's mission is to restore health to enhance the quality of life forpatients with bone disorders.BONESUPPORT was founded on 2000 and is headquartered in Lund, Sweden. | $36.1M / Venture - Series Unknown / Oct 27, 2016 | ||
| Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells toselectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular degeneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed. | $10M / Series C / Aug 09, 2016 | ||
| See all 19 investments → | |||
Co-Investors
About Lundbeckfonden Ventures
Lundbeckfond Ventures is an evergreen life science venture fund established in the autumn of 2009 and wholly owned by the Lundbeck Foundation. The structure as an evergreen fund allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. On an annual basis, LundbeckfondVentures invests up to € 50 million.Lundbeckfond Ventures is a financially driven venture fund generating returns to support the group's activities and operating independently from the Lundbeck Foundation’s controlling ownerships in H. Lundbeck A/S, ALK-Abelló and Falck.
Lundbeckfonden Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jette Bundgard
Associate
|
|||
|
Johan Kördel
Senior Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Johan Kördel invest in?
Johan Kördel invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Johan Kördel?
Public channels for Johan Kördel include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Johan Kördel last invest?
The most recent investment recorded for Johan Kördel closed in Nov 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
